Advisory Services Network’s Protara Therapeutics TARA Stock Holding History

Advisory Services Network’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000	Closed	-$4.35K	–	3987
2025 Q3	$4.35K	Buy	+1,000	New	+$3.24K	﹤0.01%	3581

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Advisory Services Network's TARA Position: Q4 2025 in Review

Advisory Services Network sold out of Protara Therapeutics (TARA) in Q4 2025, closing a stake of 1,000 shares — an estimated $4.35K sold.

Advisory Services Network first reported a position in TARA in Q3 2025 and held it in 1 quarter. The position peaked at $4.35K in Q3 2025. 105 funds tracked by Wall St. Rank hold TARA as of Q4 2025.

Advisory Services Network reported no remaining Protara Therapeutics position as of Q4 2025 after selling out during the quarter.
Advisory Services Network sold 1,000 Protara Therapeutics shares in Q4 2025, an estimated $4.35K.
Advisory Services Network first reported a position in Protara Therapeutics in Q3 2025 and held it in 1 quarter.
Advisory Services Network's Protara Therapeutics position peaked at $4.35K in Q3 2025.
105 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2025.

Based on Advisory Services Network's 13F filing for Q4 2025, filed 17 Feb 2026.